Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9267838 | 0.79 | LMNA (0.59) | ACHEATMALDH1A1KMT2ARAB9A | |
| SCHEMBL31460798 | 0.78 | SIGMAR1 (0.54) | ALDH1A1 | |
| SCHEMBL10662603 | 0.75 | TDP1 (0.53) | ATMTDP1L3MBTL1ALDH1A1PKM | |
| SCHEMBL23130278 | 0.74 | ALDH1A1 (0.53) | ALDH1A1LSSRAB9AFAAH | |
| SCHEMBL5537324 | 0.73 | TDP1 (0.47) | ACHEATMTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL5030060 | 0.72 | LSS (0.55) | ACHEL3MBTL1LSSRAB9A | |
| SCHEMBL5030058 | 0.72 | LSS (0.55) | ACHEL3MBTL1LSSRAB9A | |
| SCHEMBL9623373 | 0.72 | TDP1 (0.46) | ACHEATMTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL22532970 | 0.72 | GAA (0.68) | ACHEALDH1A1PKMKMT2AGAA | |
| SCHEMBL4797473 | 0.72 | LSS (0.57) | ACHEL3MBTL1KMT2ALSSRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | claimed |
| EP-1560823-B1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2008-07-09 | — | — | EP | claimed |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2005-12-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | OPRL1, OPRM1, OGFRL1 | ACHE 1049/4885ATM 4797/4885TDP1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.